Core Viewpoint - Jinxin Reproductive Medicine (01951) experienced a significant stock price increase of 10.48% on August 18, reaching HKD 3.48 per share with a trading volume of HKD 296 million [1] Company Overview - Jinxin Reproductive Medicine Group Limited is a leading assisted reproductive service provider in China and the United States, operating multiple hospitals and medical centers that primarily offer assisted reproductive services and related treatments [1] - According to a Frost & Sullivan report, in 2018, the company ranked third in China's assisted reproductive services market, conducting 20,958 in vitro fertilization (IVF) egg retrieval cycles, with a market share of approximately 3.1%, and ranked first among non-state-owned assisted reproductive service providers [1] Financial Performance - As of the 2024 annual report, Jinxin Reproductive Medicine reported total revenue of HKD 2.812 billion and a net profit of HKD 283 million [2] Upcoming Events - Jinxin Reproductive Medicine is scheduled to disclose its interim report for the fiscal year 2025 on August 25 [3]
锦欣生殖(01951)上涨10.48%，报3.48元/股